Biotech stocks are companies that use living organisms to make drugs and vaccines. Often, they merge cutting-edge technology with new findings in molecular science and virology to treat life ...

Jefferies analyst James Vane maintained a Buy rating on Sartorius Stedim Biotech (0RG8 – Research Report) today and set a price target of €269.00. The company’s shares closed yesterday at ...

Evaxion Biotech (EVAX) has received notice from the Nasdaq Stock Market that it has been granted a 180-day extension to comply with Nasdaq’s minimum stockholder’s equity requirement.

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...

Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...

The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...

In 2019, Stan­ford Uni­ver­si­ty pro­fes­sor Irv Weiss­man and a col­league pub­lished a pa­per that rep­re­sent­ed a new way to tar­get some ag­gres­sive can­cers.

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an early look at how receptive public investors could be to biotech listings ...